Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. diseases naid for zika virus
Show results for
Products
Services
Software

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Diseases Naid For Zika Virus Articles & Analysis

11 news found

Creative Diagnostics Advances Zika Virus Research with Novel Animal Models

Creative Diagnostics Advances Zika Virus Research with Novel Animal Models

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Zika Virus Animal Model services for scientists to understand the complex mechanisms of Zika virus infection and develop effective countermeasures. These models are valuable tools in the research and development of vaccines and therapeutics against this emerging ...

ByCreative Diagnostics


Viral Vector Manufacturing

Viral Vector Manufacturing

In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various ...

ByNuvonis


INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial ...

ByINOVIO Pharmaceuticals


Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

? Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? MV-014-212 was built on the company’s AttenuBlock platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity ? Data will be ...

ByMeissa Vaccines, Inc.


Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test

Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), to complete the development and launch of a new test for Zika virus infection. Kephera’s test is aimed at detecting Zika ...

ByKephera Diagnostics, LLC


 Siveco client GSN fights the COVID-19 epidemic using bluebee®

Siveco client GSN fights the COVID-19 epidemic using bluebee®

Fighting the COVID-19 (Corona Virus Disease) epidemic requires joint efforts! GSN Property Services, the leading German property management provider in China, is using bluebee® to monitor progress of disinfection work. Scanning of QR-coded tags in the bluebee® app ensures the traceability of actions taken against the COVID-19. GSN has also deployed the bluebee® system at two ...

BySiveco China


EPA Approves Experimental Use Permit for Field Testing of Genetically Modified Aedes aegypti Mosquitos

EPA Approves Experimental Use Permit for Field Testing of Genetically Modified Aedes aegypti Mosquitos

On May 1, 2020, the U.S. Environmental Protection Agency granted an experimental use permit (EUP) to Oxitec Ltd. (Oxitec) to field test the use of genetically engineered Aedes aegypti mosquitoes as a way to reduce populations that serve as a vector for a variety of diseases including Zika virus. The EUP is designed to test the effectiveness of genetically engineered Aedes aegypti mosquitoes as a ...

ByBergeson & Campbell, P.C.


Alveo Technologies Announces Research Collaboration with Janssen Pharmaceuticals, Inc. to Advance At-Home Testing Platform for Viral Infectious Diseases

Alveo Technologies Announces Research Collaboration with Janssen Pharmaceuticals, Inc. to Advance At-Home Testing Platform for Viral Infectious Diseases

Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal ...

ByAlveo Technologies


EPA Introduces New Graphic to Help Consumers Make Informed Choices about Insect Repellents

The U.S. Environmental Protection Agency today unveiled a new graphic that will be available to appear on insect repellent product labels. The graphic will show consumers how many hours a product will repel mosquitoes and/or ticks when used as directed. “We are working to create a system that does for bug repellents what SPF labeling did for sunscreens,” said Jim Jones, Assistant ...

ByUS EPA - Environmental Protection Agency


Scientists Develop New Vaccine to Protect Against Two Important  Diseases

Scientists Develop New Vaccine to Protect Against Two Important Diseases

USPOULTRY and the USPOULTRY Foundation announce the completion of a funded research project at North Carolina State University in Raleigh, N.C., that evaluated a new vaccine to protect again two important diseases. The project is part of the Association’s comprehensive research program encompassing all phases of poultry and egg production and processing. A brief summary of the completed ...

ByU.S. Poultry & Egg Association


Climate change`s effects on plant disease `under-researched`

Climate change`s effects on plant disease `under-researched`

Africa needs more research to address the information gaps on the impact of climate change on diseases, infections and epidemics caused by plant viruses, according to a study. Researchers at the University of Western Australia conducted a review of existing literature, and found that the research gaps include a lack of climate change-scenario modelling for diseases caused by plant viruses, and ...

BySciDev.Net

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT